Metabolic and Vascular Features of Dynamic Contrast-enhanced Breast Magnetic Resonance Imaging and 15O-Water Positron Emission Tomography Blood Flow in Breast Cancer

Academic Radiology

Volumn 15, Issue 10, 2008, Pages 1246-1254

  Eby, Peter R ^a   Partridge, Savannah C ^a   White, Steven W ^a   Doot, Robert K ^b,c   Dunnwald, Lisa K ^b   Schubert, Erin K ^b   Kurland, Brenda F ^d   Lehman, Constance D ^a   Mankoff, David A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c University of Washington   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

15O PET; Breast cancer; enhancement kinetics; MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BLOOD FLOW; BREAST CANCER; BREAST EXAMINATION; CANCER PATIENT; CLINICAL ARTICLE; HUMAN; METABOLIC RATE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BLOOD FLOW VELOCITY; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; WATER;

EID: 51449121001     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2008.03.019     Document Type: Article

References (49)

1. Chen J.H., Feig B., Agrawal G., et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112 (2007) 17-26
2. Chen X., Moore M.O., Lehman C.D., et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 11 (2004) 1115-1124
3. Daldrup-Link H.E., Okuhata Y., Wolfe A., et al. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Microcirculation 11 (2004) 387-396
4. Jansson T., Westlin J.E., Ahlstrom H., Lilja A., Langstrom B., and Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?. J Clin Oncol 13 (1995) 1470-1477
5. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 43 (2002) 500-509
6. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44 (2003) 1806-1814
7. Martincich L., Montemurro F., De Rosa G., et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83 (2004) 67-76
8. Partridge S.C., Gibbs J.E., Lu Y., et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184 (2005) 1774-1781
9. Semple S.I., Gilbert F.J., Redpath T.W., et al. Correlation of MRI/PET rim enhancement in breast cancer: A delivery related phenomenon with therapy implications?. Lancet Oncol 4 (2003) 759
10. Semple S.I., Staff R.T., Heys S.D., et al. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 17 (2006) 1393-1398
11. Tseng J., Dunnwald L.K., Schubert E.K., et al. 18F-FDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 (2004) 1829-1837
12. Wahl R.L., Zasadny K., Helvie M., Hutchins G.D., Weber B., and Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11 (1993) 2101-2111
13. Wasser K., Klein S.K., Fink C., et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13 (2003) 80-87
14. Yu H.J., Chen J.H., Mehta R.S., Nalcioglu O., and Su M.Y. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 26 (2007) 615-623
15. Pham C.D., Roberts T.P., van Bruggen N., et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16 (1998) 225-230
16. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
17. Wilmes L.J., Pallavicini M.G., Fleming L.M., et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25 (2007) 319-327
18. Berg W.A., Gutierrez L., NessAiver M.S., et al. Diagnostic accuracy of mammography, clinical examination, US, and metabolic rate imaging in preoperative assessment of breast cancer. Radiology 233 (2004) 830-849
19. Bone B., Szabo B.K., Perbeck L.G., Veress B., and Aspelin P. Can contrast-enhanced metabolic rate imaging predict survival in breast cancer?. Acta Radiol 44 (2003) 373-378
20. Esserman L., Hylton N., George T., and Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 5 (1999) 13-21
21. Hylton N.M. Vascularity assessment of breast lesions with gadolinium-enhanced metabolic rate imaging. Magn Reson Imaging Clin N Am 7 (1999) 411-420, x
22. Knopp M.V., Brix G., Junkermann H.J., and Sinn H.P. metabolic rate mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 2 (1994) 633-658
23. Kuhl C.K., Mielcareck P., Klaschik S., et al. Dynamic breast metabolic rate imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology 211 (1999) 101-110
24. Li K.L., Henry R.G., Wilmes L.J., et al. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magn Reson Med 58 (2007) 572-581
25. Padhani A.R., Hayes C., Assersohn L., et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced metabolic rate imaging: Initial clinical results. Radiology 239 (2006) 361-374
26. Shames D.M., Kuwatsuru R., Vexler V., Muhler A., and Brasch R.C. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: A quantitative noninvasive technique. Magn Reson Med 29 (1993) 616-622
27. Knopp M.V., Weiss E., Sinn H.P., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10 (1999) 260-266
28. Schelling M., Avril N., Nahrig J., et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18 (2000) 1689-1695
29. Smith I.C., Welch A.E., Hutcheon A.W., et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18 (2000) 1676-1688
30. Wilson C.B., Lammertsma A.A., McKenzie C.G., Sikora K., and Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52 (1992) 1592-1597
31. Beaney R.P., Lammertsma A.A., Jones T., McKenzie C.G., and Halnan K.E. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1 (1984) 131-134
32. Zasadny K.R., Tatsumi M., and Wahl R.L. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30 (2003) 274-280
33. Goerres G.W., Michel S.C., Fehr M.K., et al. Follow-up of women with breast cancer: Comparison between MRI and FDG PET. Eur Radiol 13 (2003) 1635-1644
34. Muramoto S., Uematsu H., Sadato N., et al. H(2) (15)0 positron emission tomography validation of semiquantitative prostate blood flow determined by double-echo dynamic MRI: A preliminary study. J Comput Assist Tomogr 26 (2002) 510-514
35. Sakuma H., Koskenvuo J.W., Niemi P., et al. Assessment of coronary flow reserve using fast velocity-encoded cine metabolic rate imaging: Validation study using positron emission tomography. AJR Am J Roentgenol 175 (2000) 1029-1033
36. Ye F.Q., Berman K.F., Ellmore T., et al. H(2)(15)O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans. Magn Reson Med 44 (2000) 450-456
37. Partridge S.C., Heumann E.J., and Hylton N.M. Semi-automated analysis for MRI of breast tumors. Stud Health Technol Inform 62 (1999) 259-260
38. Sokoloff L., Reivich M., Kennedy C., et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28 (1977) 897-916
39. Phelps M.E., Huang S.C., Hoffman E.J., Selin C., Sokoloff L., and Kuhl D.E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 6 (1979) 371-388
40. Reivich M., Alavi A., Wolf A., et al. Glucose metabolic rate kinetic model parameter determination in humans: The lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 5 (1985) 179-192
41. Reivich M., Kuhl D., Wolf A., et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44 (1979) 127-137
42. Su H., Bodenstein C., Dumont R.A., et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12 (2006) 5659-5667
43. Brix G., Henze M., Knopp M.V., et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: Initial experience. Eur Radiol 11 (2001) 2058-2070
44. Alger J.R., Frank J.A., Bizzi A., et al. Metabolism of human gliomas: Assessment with H-1 metabolic rate spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 177 (1990) 633-641
45. Luyten P.R., Marien A.J., Heindel W., et al. Metabolic imaging of patients with intracranial tumors: H-1 metabolic rate spectroscopic imaging and PET. Radiology 176 (1990) 791-799
46. Brix G., Kiessling F., Lucht R., et al. Microcirculation and microvasculature in breast tumors: Pharmacokinetic analysis of dynamic metabolic rate image series. Magn Reson Med 52 (2004) 420-429
47. Hayes C., Padhani A.R., and Leach M.O. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15 (2002) 154-163
48. Pickles M.D., Lowry M., Manton D.J., Gibbs P., and Turnbull L.W. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91 (2005) 1-10
49. Thukral A., Thomasson D.M., Chow C.K., et al. Inflammatory breast cancer: Dynamic contrast-enhanced metabolic rate in patients receiving bevacizumab-Initial experience. Radiology 244 (2007) 727-735